Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Low-dose Esketamine on Postoperative Depression in Breast Cancer Patients
NCT04850937Completed
- Sponsor
- Yangzhou University
- Start
- Feb 2021
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of esketamine in major depressive disorder (MDD) (2 arms), sponsored by Yangzhou University. Primary endpoint: Hamilton Depression Scale score at 3 months. Started Feb 2021; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04850937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04850937.